Saturday - December 21, 2024
UT-MD Anderson Cancer Center: ASH - Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory Disorder
December 10, 2024
HOUSTON, Texas, Dec. 10 (TNSres) -- The University of Texas MD Anderson Cancer Center issued the following news release:

* * *

Researchers observed 100% response rate on Phase Ib trial for patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis

* * *

ABSTRACT: 805 (https://ash.confex.com/ash/2024/webprogram/Paper204230.html)

* * *

SAN DIEGO - Adult patients with newly diagnosed malignancy . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products